tbuckley/cabot-search huggingface dataset:
SAT0282 Frequency and Predictors of Attainment of The Lupus Low Disease Activity State (LLDAS) in A Cross Sectional Study of Sle Patients in The Asia Pacific
Authors: V. Golder, R. Kandane-Rathnayake, A. Hoi, W. Louthrenoo, Y. An, Z.G. Li, S.F. Luo, S. Sockalingam, C.S. Lau, A.L. Lee, M.Y.T. Mok, A. Lateef, K. Franklyn, S.V. Navarra, L. Zamora, Y.-J. Wu, L. Hamijoyo, M. Chan, S. O'Neill, F. Goldblatt, M. Huq, M. Nikpour, E.F. Morand
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a heterogeneous disease characterised by fluctuating disease activity. A low disease activity endpoint, the Lupus Low Disease Activity State (LLDAS), was recently reported and retrospective validation showed that time spent in LLDAS translated into reduced damage accrual (Franklyn, Ann Rheum Dis, 2015). A large prospective study to validate LLDAS in a multiethnic cohort of lupus patients from the Asia Pacific Region is underway. <h3>Objectives</h3> To describe the frequency and identify the predictors of fulfilling criteria for LLDAS in baseline visit data from a large multinational multiethnic cohort of patients with SLE in nine Asia Pacific countries. <h3>Methods</h3> Prospectively collected baseline visit data from 1846 SLE patients enrolled in a longitudinal study were analysed cross sectionally against the recently published definition of LLDAS, and patient characteristics associated with LLDAS attainment determined. <h3>Results</h3> LLDAS criteria were met by 44% of patients at a single baseline visit. Stepwise multivariable logistic regression revealed that patients with shorter disease duration were less likely to be in LLDAS (OR 0.31, 95% CI 0.19–0.49, p&lt;0.001). Likewise, discoid rash (OR 0.66, 95% CI 0.49–0.89, p=0.006), renal disease (OR 0.60, 95% CI 0.48–0.75, p&lt;0.001), elevated double stranded DNA (OR 0.65, 95% CI 0.53–0.81, p&lt;0.001) or hypocomplementaemia (OR 0.52, 95% CI 0.40–0.67, p&lt;0.001) were negatively associated with LLDAS attainment. Significant differences in LLDAS attainment between countries were observed, and higher national social wealth as measured by the Gross Domestic Product per capita was positively associated with LLDAS (OR 1.57, 95% CI 1.25–1.98, p&lt;0.001). <h3>Conclusions</h3> Low disease activity was observed in less than half of SLE patients at a single point in time. Disease duration and phenotype, as well as national social wealth, were predictive of LLDAS attainment. <h3>Disclosure of Interest</h3> None declared
A Novel Perspective On Hematopoietic Stem/Progenitor Cell Homing - an Expanding Family of Bone Marrow Homing Factors That Can Support SDF-1-Mediated Homing or Even Replace SDF-1
Authors: Gabriela Schneider, Kim ChiHwa, Ahmed Abdel-Latif, Anna Janowska-Wieczorek, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2012)
Different Epstein-Barr Virus DNA Load and Immune Reconstitution Following Hematopoietic Stem Cell Transplantation Depending on Antithymocyte Globulin Preparation.
Authors: Bernd Gruhn, Astrid Meerbach, Ralf Häfer, Ilona Wolff, Isabella Schiller, Dietlinde Fuchs, Johann Hermann, Peter Wutzler, Felix Zintl
Journal: Blood (2004)
THU0358 Hip Joint Avascular Necrosis in A Multi-Ethnic Systemic Lupus Erythematosus Cohort
Authors: S.S. Shaharir, R. Mohd, R. Mustafar, N.S. Shahril
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Avascular necrosis of bone (AVN) is a well known complication in patients with systemic lupus erythematosus (SLE). <h3>Objectives</h3> To determine the prevalence of avascular necrosis (AVN) involving hip joint among SLE patients and its associated factors. <h3>Methods</h3> Consecutive SLE patients attending outpatient follow-up clinics in National University of Malaysia and Putrajaya Hospital, Malaysia from 2004 until 2014 with confirmed avascular necrosis of hip joint on magnetic resonance imaging (MRI) were reviewed. Demographics and disease characteristics of patients with AVN complications were compared with other lupus controls. <h3>Results</h3> A total of 300 patients were reviewed and majority of them were Malays (175, 58.3%) followed by Chinese (107, 35.7%), Indian (15, 5%) and others (3, 1%). Eighteen patients (6%) had hip joint AVN and more than two-thirds were bilateral (14 patients, 77.8%). The median onset of AVN was 3 (IQR 4.25) years from diagnosis of lupus. A higher proportion of patients who did not received hydroxychloroquine (HCQ) developed AVN compared to those receiving HCQ (50% vs 24.8%, p=0.02). On the other hand, prednisolone dose ≥60mg daily for at least 2 weeks were associated with a higher prevalence of AVN (55.6% vs 23.4%, p=0.005). Positive antiphospholipid antibody (aPL) was also associated with higher prevalence of AVN (55.6% vs 27%, p=0.01). Multivariable logistic regression analysis revealed that the independent predictors of AVN were prednisolone dose ≥60mg OD [OR 3.7 (95% CI 1.3–9.9)] and aPL positivity [OR3.1 (95% CI 1.1–8.3)]. HCQ use was independently associated with lower prevalence of AVN [OR 0.3 (95% CI 0.1–0.9)]. <h3>Conclusions</h3> Hip joint AVN was significantly associated with positive aPL, prednisolone dose ≥60mg daily for at least 2 weeks while HCQ use was demonstrated to be associated with lower hip AVN prevalence. <h3>References</h3> MY Mok et al, Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: Is there a role for antiphospholipid antibodies? Ann Rheum Dis 2000;59:462–467 J Lee et al, Osteonecrosis of the hip in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus 2014; 23 (1): 39–45. <h3>Disclosure of Interest</h3> None declared
Multiple behaviour change intervention for diarrhoea control in Lusaka, Zambia: a cluster randomised trial
Authors: Katie Greenland, Jenala Chipungu, Val Curtis, Wolf-Peter Schmidt, Zumbe Siwale, Mweetwa Mudenda, Joyce Chilekwa, James J Lewis, Roma Chilengi
Journal: The Lancet Global Health (2016)

Effective prevention and control of diarrhoea requires caregivers to comply with a suite of proven measures, including exclusive breastfeeding, handwashing with soap, correct use of oral rehydration salts, and zinc administration. We aimed to assess the effect of a novel behaviour change intervention using emotional drivers on caregiver practice of these behaviours.We did a cluster randomised controlled trial in Lusaka Province, Zambia. A random sample of 16 health centres (clusters) were selected from a sampling frame of 81 health centres in three of four districts in Lusaka Province using a computerised random number generator. Each cluster was randomly assigned 1:1 to either the intervention-clinic events, community events, and radio messaging-or to a standard care control arm, both for 6 months. Primary outcomes were exclusive breastfeeding (self-report), handwashing with soap (observation), oral rehydration salt solution preparation (demonstration), and zinc use in diarrhoea treatment (self-report). We measured outcome behaviours at baseline before start of intervention and 4-6 weeks post-intervention through repeat cross-sectional surveys with mothers of an infant younger than 6 months and primary caregivers of a child younger than 5 years with recent diarrhoea. We compared outcomes on an intention-to-treat population between intervention and control groups adjusted for baseline behaviour. The study was registered with ClinicalTrials.gov, number NCT02081521.Between Jan 20 and Feb 3, 2014, we recruited 306 mothers of an infant aged 0-5 months (156 intervention, 150 standard care) and 343 primary caregiver of a child aged 0-59 months with recent diarrhoea (176 intervention, 167 standard care) at baseline. Between Oct 20 to Nov 7, 2014, we recruited 401 mothers of an infant 0-5 months (234 intervention, 167 standard care) and 410 primary caregivers of a child 0-59 months with recent diarrhoea (257 intervention, 163 standard care) at endline. Intervention was associated with increased prevalence of self-reported exclusive breastfeeding of infants aged 0-5 months (adjusted difference 10·5%, 95% CI 0·9-19·9). Other primary outcomes were not affected by intervention. Cluster intervention exposure ranged from 11-81%, measured by participant self-report with verification questions. Comparison of control and intervention clusters with coverage greater than 35% provided strong evidence of an intervention effect on oral rehydration salt solution preparation and breastfeeding outcomes.The intervention may have improved exclusive breastfeeding (assessed by self-reporting), but intervention effects were diluted in clusters with low exposure. Complex caregiver practices can improve through interventions built around human motives, but these must be implemented more intensely.Absolute Return for Kids (ARK) and Comic Relief.
AB0613 Anti-C1q Autoantibodies Are Frequently Detected in Patients with Systemic Sclerosis and Lung Fibrosis
Authors: C. Liaskos, S. Rentouli, T. Simopoulou, A. Mavropoulos, G.L. Norman, I. Alexiou, C.G. Katsiari, D.P. Bogdanos, L.I. Sakkas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-C1q autoantibodies are associated with systemic lupus erythematosus (SLE) but their presence in other rheumatic diseases has not been investigated in great detail. <h3>Objectives</h3> We aim to assess the clinical significance of anti-C1q autoantibodies in systemic sclerosis (SSc). <h3>Methods</h3> Seventy five patients with SSc (median age 59 years; females, 61; diffuse cutaneous SSc 35, limited cutaneous SSc, 40) were studied. Thirty eight patients with SLE, 25 patients with Sjögren9s syndrome (SjS), 19 with rheumatoid arthritis (RA), and 31 healthy individuals (NC) were also included. IgG anti-C1q antibodies were tested by ELISA. Anti-nuclear antibodies (ANA), and SSc-specific autoantibodies were also tested. <h3>Results</h3> A receiver operator characteristic curve (ROC) confirmed that the cut off at 20 RU/mL for the anti-C1q test (specificity, 0.94, 95% CI, 0.79 to 0.99, LR: 5.0) was appropriate. Anti-C1q antibodies were present in 32.0% of SSc patients compared to 16.0% SS, 10.5% RA patients (p&lt;0.05, for all) and in 6.5% NC (p&lt;0.01). The frequent presence of anti-C1q antibodies in SLE was confirmed (13/38, 34.2%). Amongst the 24 anti-C1q (+) SSc patients, 15 had high/moderate levels (&gt;40 RU/mL). There was no association between anti-C1q antibodies and anti-topoisomerase I, anti-centromere, or anti-RNA polymerase III antibodies. Anti-C1q antibodies were associated with male sex (p=0.04) and lung fibrosis (LF) (p=0.008), and co-occurrence of LF and skin ulcers (p=0.006). Ulcers were more prevalent in anti-C1q(+) than anti-C1q(−) patients (64% vs 44%), but the difference did not reach statistical significance (p=0.1). <h3>Conclusions</h3> Anti-C1q antibodies were frequently detected in SSc, were associated with PF and co-occurrence of PF and skin ulcers and may contribute to the autoimmune process in SSc. <h3>Acknowledgement</h3> Fianancial support by ELKE, University of Thessaly <h3>Disclosure of Interest</h3> None declared
THU0036 Identifying Clinical Factors Associated with Lower Disease Activity during Pregnancy in Patients with Rheumatoid Arthritis To Select Those Patients in Whom Medication Can Be Safely Tapered
Authors: H. Ince-Askan, J.M. Hazes, R.J. Dolhain
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pregnancy is the only natural condition in which Rheumatoid Arthritis (RA) remits spontaneously in approximately half of the pregnancies [1]. Many physicians try to taper or stop medication when a women conceives in order to prevent drug related side effects for mother and child. However, 50% of the patients still has active disease in the third trimester of pregnancy<sup>1</sup>. Factors that can identify patients in whom medication can be safely tapered during pregnancy are therefore needed. <h3>Objectives</h3> To determine clinical factors associated with lower disease activity in the third trimester during pregnancy in women with Rheumatoid Arthritis (RA) and thereby to identify patients in whom medication can be safely tapered during pregnancy. <h3>Methods</h3> This study is embedded in the Pregnancy induced Amelioration of Rheumatoid Arthritis (PARA)-study, a nationwide prospective cohort study. There was data available on 190 pregnancies from first trimester unto delivery. Disease activity was measured using the Disease Activity Score in 28 joints (DAS28). A multivariate linear regression analysis was performed on the DAS28 in the third trimester. Independent covariates in these models: the DAS28 in the first trimester, prednisone and sulfasalazine use in the first trimester, parity, methotrexate use in past, autoantibody status (either rheumatoid factor or ACPA positive), presence of erosions and duration of RA. <h3>Results</h3> In the multivariate linear regression model, see table 1., a higher DAS28 in the first trimester, the use of prednisone and the presence of autoantibodies were statistically significantly associated with a higher DAS28 in the third trimester (p-values &lt;0.001, 0.032 and 0.014 respectively). <h3>Conclusions</h3> The DAS28 in the first trimester, the autoantibody status and the use of prednisone were associated with RA disease activity in the third trimester. Female RA patients who have a lower DAS28 in the first trimester are likely to have lower disease activity in the third trimester, especially if they are autoantibody negative and if they do not use prednisone. In these patients, it may be considered to safely taper their medication. <h3>References</h3> de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59:1241–8. <h3>Funding</h3> Dr. R.J.E.M. Dolhain received unrestricted research grants from the Dutch Arthritis Association (Reumafonds), a non-commercial fund raising organization, and from UCB Pharma BV. <h3>Conflicts of interest</h3> None. <h3>Disclosure of Interest</h3> None declared
Case 43-1964
Authors: Farahe Maloof, Robert E. Scully
Journal: New England Journal of Medicine (1964)

Presentation of Case First admission. A seventy-eight-year-old man entered the hospital because of hoarseness.Six years previously a biopsy of the larynx, which was performed because of hoarseness, revealed chronic inflammation. He was subsequently well until two months before admission, when hoarseness began to recur intermittently. He had had tuberculosis fifty years earlier and had smoked one package of cigarettes daily for many years.Physical examination revealed thickening of the vocal cords, with diminished mobility on the right side. X-ray films of the chest (Fig. 1) showed extensive fibrosis, collapse and bleb formation in the upper lobe of the left . . .
AB1055 The Risk of Obstructive Sleep Apnea in 52994 Patients with Systemic Autoimmune Diseases in Taiwan: A Nationwide Population-Based Study
Authors: W.-S. Chen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several pathological mechanisiums may underlies an association between sleep apnea and autoimmune diseases. There are few evidances of increasing risk of OSA in patients with rheumatoid arthritis, ankylosing spondylitis. The risk of OSA in RA or Sjogren syndrome (SS)was thought to be attributed to upper airway dryness with a resulting in a colappsibility or temporomandibular joint involvement (1,2). The association between asystemic autoimmune disease nd obstructive sleep apnea were not clear in Asian. We hypothesized that autoimmune diseases would predispose patients to the occurance of OSA. <h3>Objectives</h3> To explore the association between the obstructive sleep apnea (OSA) and autoimmune diseases <h3>Methods</h3> 52994 adult patients with systemic autoimmune diseases diagnoses recorded in the Taiwan National Health Insurance Research Database between 2002 and 2011, after excluding those with antecedent obstructive sleep apnea. A comparison cohort of 211976 participants was formed by age-, gender-matched controls. Multivariable Cox regression was performed on the two cohorts to compute the risk of OSA during follow-up period. <h3>Results</h3> In patients with systemic autoimmune diseases, the overall risk for incident OSA was significantly higher than in controls (adjusted hazard ratio [HR] =1.58, 95% confidence interval [CI] =1.38–1.82). Risk of OSA in individual autoimmune diseases, including rheumatoid arthritis (RA), Sjögren9s syndrome (SS) and Behçet disease, was also significantly higher than in controls (HR [95% CI] for RA, primary SS, secondary SS and Behçet disease were 1.36 [1.12–1.63], 2.28 [1.68–3.10], 2.88 [2.14–3.87] and 2.39 [1.43–4.01], respectively). Increased risk for systemic lupus erythematosus did not reach statistical significance (HR: 0.79 [0.49–1.28]). <h3>Conclusions</h3> Patients with systemic autoimmune diseases including of RA, primary or secondary SS and Behçet disease were associated with a higher risk for developing OSA. <h3>References</h3> Usmani ZA, Hlavac M, Rischmueller M et al. Sleep disordered breathing in patients with primary Sjögren9s syndrome: a group controlled study Sleep Med. 2012;13(8):1066–70 Reading SR, Crowson CS, Rodeheffer RJ et al. Do rheumatoid arthritis patients have a higher risk for sleep apnea? J Rheumatol. 2009;36(9):1869–72 <h3>Disclosure of Interest</h3> None declared
Primary Treatment for Acute Graft-Versus-Host Disease (GVHD): A Single-Center Analysis of 458 Japanese Patients.
Authors: Takahiro Fukuda, Toshihiro Takahashi, Yukiko Iisaka, Fusako Ohara-Waki, Sung-Won Kim, Shin-ichiro Mori, Ryuji Tanosaki, Atsushi Makimoto, Kensei Tobinai, Yoichi Takaue
Journal: Blood (2007)
A Role of Platelet Activation in Lacunar Stroke?
Authors: Nadine Ajzenberg, Philippa C Lavallee, Julien Labreuche, Dorothee Faille, marie-Genevieve Huisse, Fernando Gongora-Rivera, Arturo Jaramillo, David Brenner, Dominique Deplanque, Isabelle F Klein, Pierre-Jean Touboul, Eric Vicaud, Pierre Amarenco
Journal: Blood (2012)
Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Authors: Amer M. Zeidan, Jessica B. Long, Jane Hall, Rong Wang, Scott F Huntington, Gregory Abel, Thomas Prebet, Nikolai A. Podoltsev, Cary P. Gross, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff
Journal: Blood (2015)
Left ventricular deformation at rest predicts exercise‐induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea
Authors: Tor Biering‐Sørensen, Mário Santos, Jose Rivero, Shane D. McCullough, Erin West, Alexander R. Opotowsky, Aaron B. Waxman, David M. Systrom, Amil M. Shah
Journal: European Journal of Heart Failure (2016)
AB0779 Multidisciplinary Out-Patient Clinic (Reumatology-Endocrinology) for Patients with Complex Metabolic Bone Disease: 2 Years Experience
Authors: E. Casado, O. Giménez, M. Arévalo, M. Rigla, M. Larrosa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoporosis (OP) is a highly prevalent metabolic bone disease and may be secondary to endocrine diseases. In these cases the assessment of a rheumatologist and an endocrinologist may be complementary and beneficial for both the patient and the hospital. <h3>Objectives</h3> To describe the experience of two years of a multidisciplinary out-patient consultation Rheumatology-Endocrinology in the care of patients with metabolic bone diseases. <h3>Methods</h3> A multidisciplinary outpatient clinic Rheumatology-Endocrinology was set in December 2013 to assess patients coming from one or another specialty with some metabolic bone disease that could benefit from both a rheumatologist and an endocrinologist. The consultation takes place between 12–14h, on a monthly basis. Demographic characteristics, department of origin, diagnosis, complementary tests, and implemented changes in both the diagnosis and treatment were recorded. Data collected during the years 2014 and 2015 are presented. <h3>Results</h3> In these 2 years there have been 20 consultation sessions (10 per year), with a total of 103 visits. 54 patients (43 women and 11 men) were treated as first visit. Age 57±15 years (range 29–88). There have been 27 successive visits (ratio first/successive 2/1) and in 22 cases the patients did not attend the appointment. 63% of patients (34) came from Endocrinology and 31% (17) from Rheumatology. Three patients came from other services (Internal Medicine, Primary Care and Physical Therapy). Pathologies in order of frequency derived from Endocrinology were OP in the context of primary hyperparathyroidism (29%), hypogonadism (26%), bariatric surgery (15%) and glucocorticoid induced OP (6%). In 6 patients the inquiry was not related to bone metabolism and the diagnoses were: gout, psoriatic arthritis, osteoarthritis, fibromyalgia, among others. The pathologies most frequently derived from Rheumatology were primary hyperparathyroidism (41%), hypogonadism (18%) and adrenal insufficiency in patients with chronic corticosteroid therapy (12%). In 62% of patients referred from Endocrinology and in 65% of patients from Rheumatology underwent some change, either diagnosis or treatment. <h3>Conclusions</h3> A multidisciplinary consultation Rheumatology-Endocrinology improves communication between the two specialties and facilitates the standardization of diagnostic and therapeutic criteria. It also represents a convenience for the patient and savings for the hospital, as the number of visits and complementary tests are reduced. <h3>Disclosure of Interest</h3> None declared
FRI0277 Six-Minute Walk Test in Systemic Sclerosis Patients without Interstitial Lung Disease and Pulmonary Arterial Hypertension: Table 1.
Authors: E. Vandecasteele, K. Melsens, F. De Keyser, M. De Pauw, E. Deschepper, S. Decuman, Y. Piette, G. Brusselle, V. Smith
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Although the six-minute walk test (6MWT) is used for evaluating ILD and PAH in clinical practice, no data are available on six-minute walk distance (6MWD) in SSc without ILD and PAH. <h3>Objectives</h3> This study wants to evaluate the 6MWT at baseline and 6-month follow-up in a cohort of unselected SSc patients without ILD and PAH. <h3>Methods</h3> Prospectively collected data of the 6MWTs at baseline and 6-month follow-up of 300 consecutive SSc patients, included in the Ghent University Hospital Systemic Sclerosis Cohort between May 2006 and April 2015 were analysed. <h3>Results</h3> 98% (286/292) of the SSc patients performed a 6MWT at baseline or 6-month visit, after exclusion of 8 of the 300 SSc patients due to logistic problems. Two patients were unable to perform a 6MWT due to leg amputation and 4 due to immobility. 76% of the patients were female with a mean age of 51±14 years. Six patients had PAH, five had ILD and four were not evaluated with HRCT. Eventually 271 SSc patients without ILD and PAH performed a 6MWT at baseline or 6-month visit and 193 at both moments. The mean 6MWD of those 271 SSc patients was 460±108m. Patients in the diffuse cutaneous (DcSSc) subgroup (422±118m) walked less than in the limited (LSSc) subgroup (476±109m, p=0.02) and tended to walk less than in the limited cutaneous (LcSSc) subgroup (463±101m, p=0.06). In 193 SSc patients without ILD and PAH who walked at both moments, there was no significant difference between the 6MWDs (mean difference 2.11m 95%CI [-6.75m; 10.98m], p=0.64). <h3>Conclusions</h3> In SSc, execution of the 6MWT is feasible, as 98% of the SSc patients were able to perform a test. The baseline mean 6MWD of 271 SSc patients without ILD and PAH is 460±108m and is clinically stable over a 6 months period. The DcSSc subgroup walks less than the LSSc subgroup and the LcSSc subgroup. <h3>Disclosure of Interest</h3> None declared